NASDAQ:PODD Insulet Q3 2026 Earnings Date & Estimates $134.47 +0.11 (+0.08%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$134.50 +0.03 (+0.02%) As of 07:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Insulet is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Insulet in Q3 2026Insulet is expected to post earnings of $1.59 per share on revenue of $833.13 million. In the same quarter a year earlier Insulet reported $1.24 per share on revenue of $521.70 million. Insulet last reported on August 5, 2026, posting $1.66 per share and beating the $1.47 consensus estimate. Insulet has beaten the consensus EPS estimate in 8 of its last 8 quarters.Consensus EstimatesConsensus EPS$1.59Expected Revenue$833.13 millionPrior-Year EPS$1.24Prior-Year Revenue$521.70 millionExpected EPS Growth+28.2%Expected Revenue Growth+59.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$1.66 (Beat by +$0.19)Last Quarter Revenue$801.70 millionEPS Beat Rate8 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Insulet Q3 2026 Earnings FAQ When does Insulet report Q3 2026 earnings? Insulet (NASDAQ:PODD) has confirmed it will report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. What time is Insulet's Q3 2026 earnings call? Insulet's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Insulet? Analysts expect Insulet to post earnings of $1.59 per share for Q3 2026. How much revenue is Insulet expected to report? The consensus revenue estimate for Insulet is $833.13 million for Q3 2026. Insulet Earnings HeadlinesBarclays initiates coverage of Insulet with equal-weight ratingOctober 8 at 7:04 AM | msn.comInsulet (NASDAQ:PODD) Stock Moved Up to Hold by BarclaysOctober 8 at 6:06 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 9 at 1:00 AM | The Oxford Club (Ad)Analysts Offer Insights on NA Companies: Insulet (PODD) and General Motors (GM)October 1, 2026 | theglobeandmail.comInsulet to Announce Third Quarter 2026 Financial Results on November 4, 2026October 1, 2026 | finance.yahoo.comInsulet Corporation (NASDAQ:PODD) Stock Now Rated "Hold" by Wall Street AnalystsSeptember 30, 2026 | americanbankingnews.comSee More Insulet Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Insulet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insulet and other key companies, straight to your email. Email Address About InsuletInsulet (NASDAQ:PODD) is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps. Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system. The company also offers related mobile applications, controllers and digital services intended to support diabetes management and system connectivity. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet serves customers through commercial operations in the United States and international markets, including Canada, Europe and Australia. James Hollingshead serves as the company’s president and chief executive officer.View Insulet ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
